Class 2 medicines recall: Nacrez 75 microgram Film-coated Tablets (Desogestrel) PL 00289/1706
Read the official alert on GOV.UK — MedRegWatch re-presents it; GOV.UK is the authoritative source.
| Class | Class 2 |
|---|---|
| Type | Medicines recall/notification |
| Issued | 19 Oct 2016 |
| Reference | EL (16)A/14 |
Product information
EL number
EL (16)A/14
MDR number
MDR 37-08/16
Company name
Teva UK Limited
Product description
| Batch Number | Expiry Date | Pack Size | First distributed |
|---|---|---|---|
| N47810 | 31/01/2017 | 84 (3 x 28) | Apr-14 |
| N47811 | 31/01/2017 | 84 (3 x 28) | Jun-14 |
| N47812 | 31/01/2017 | 84 (3 x 28) | Jun-14 |
| N47813 | 31/01/2017 | 84 (3 x 28) | Jul-14 |
| N47815 | 31/01/2017 | 84 (3 x 28) | Dec-14 |
| N47816 | 31/01/2017 | 84 (3 x 28) | Jan-15 |
| N47823 | 30/04/2017 | 84 (3 x 28) | Jul-15 |
| N47824 | 30/04/2017 | 84 (3 x 28) | May-15 |
| O19870 | 31/10/2017 | 84 (3 x 28) | Oct-15 |
| O19871 | 31/10/2017 | 84 (3 x 28) | Sep-15 |
| R35105 | 30/06/2018 | 84 (3 x 28) | Mar-16 |
| R35106 | 30/06/2018 | 84 (3 x 28) | Apr-16 |
Brief description of the problem
Teva UK Limited is recalling the above batches because out of specification results for impurities were obtained during routine stability testing. No complaints relating to this issue have been received by the company to date.
Women currently using this product are advised to finish the pack and if they have any concerns they should speak to their doctor or pharmacist.
Remaining stock of these batches should be quarantined and returned to the original supplier for credit.
For stock enquiries, please contact Teva UK Limited Customer Service on 0800 590 502.
For medical information enquiries please contact Teva UK Limited by phone on 0207 5407117 or by email to medinfo@teva.com.
Download document
Nacrez 75 microgram Film-coated Tablets - Desogestrel - class 2 medicines recall
Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. NHS Regional teams: please cascade to relevant clinics, general practitioners and community pharmacists.